Logo Image
|Articles|June 13, 2017

Painkillers Market “to hit $28.8 billion by 2023”

The global market for pain therapeutics is predicted to increase from $19.7 billion in 2016 to around $28.8 billion in 2023, a 5.5% growth, according to business intelligence provider GBI Research.

The company’s latest report states that 817 products are included in pain therapeutics-63% of which are in the early drug development stages. The first drugs in this class are expected to receive approval in 2018, including Teva’s Fremanezumab, Alder’s Eptinezumab, Amgen and Novartis’ Erenumab and Eli Lilly’s Galcanezumab.

It is likely that the introduction of CGRPR antagonists to the market will change the treatment of migraine-as they demonstrate strong efficacy in migraine prevention via monthly injection. GBI Research expects orally administered CGRPR antagonists to gain approval from 2020.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Addressing MFN Innovation Concerns
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Read more